search
Back to results

DiabetesFlex - Patient Involvement and Patient-reported Outcome Measures in Type 1 Diabetes

Primary Purpose

Type1 Diabetes Mellitus

Status
Completed
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
DiabetesFlex
Sponsored by
Annesofie Lunde Jensen
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Type1 Diabetes Mellitus focused on measuring Self-management, Patient Activeted measure, Patient-reported outcome, Type 1 diabetes Mellitus, Non-inferiority study

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Age over 18 years Have had T1DM for more than 1 years Be able to use the Danish-language general website on healthcare www.sundhed.dk Be mentally well functioning Understand and read Danish Access to internet

Sites / Locations

  • Aahurs University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

No Intervention

Arm Label

DiabetesFlex

Standard care

Arm Description

In DiabetesFlex intervention, patients are offered 3 consultations/year. One mandatory consultations (30 minutes). The patient, an endocrinologist and a diabetes nurse attend. Two optional consultations, patients can choose between face-to-face consultations, a telephone consultation or to cancel the consultation. Ahead of the consultations, patients fill out the AmbuFlex Diabetes questionnaire and deliver a blood and urine sample. Based on the patient's response to the AmbuFlex Diabetes questionnaire, the result of the blood sample and the urine sample, the diabetes nurse assign the patient to a face-to-face consultation, a telephone consultation or no consultation with an endocrinologist, a diabetes nurse or a dietician.

Standard diabetes care consists of 3 consultations (15 minutes)/year with a physician or a diabetes nurse by turns. Ahead of the consultation patients send in a blood sample for measuring HgA1c, urine sample for measuring urin-albumin creatinin ratio and other blood samples depending of arrangements made in the last consultation. Once a year in relation to a consultation, patients fill in the Problem Area In Diabetes (PAID) (20) scale together. Furthermore, based on the patients or healthcare professional judgement, patients see a dietician when needed.

Outcomes

Primary Outcome Measures

HbA1c
Non-inferiority with respect to HbA1c

Secondary Outcome Measures

General health will be assessed by items from the SF-36 questionnaire
General health will be measured at baseline and after 15 mounth
Health literacy will be assessed by The Health Literacy Questionnaire (sub scale 6 and 9)
Health literacy will be measured at baseline and after 15 months.
Well-being will be assessed by the WHO-5 Well-being Index
Well-being will be measured at baseline and after 15 months.
Patient Activated Measure (PAM)
Patient Activated Measure (PAM) will be measured at baseline and after 15 months.
"Generic questions concerning patient involvement" is validate by "DEFACTUM"
Patient involvement will be measured at baseline and after 15 months.
The problem Areas In Diabetes Scale (PAID)
PAID will be measured at baseline and after 15 months.
Blood pressure
Blood pressure will be measured at baseline and after 15 months.
Urine albumine/creatinine ratio
urine albumine/creatinine ratio will be measured at baseline and after 15 months.
Number and type consultations
Consultations consists of face-to-face, telephone, cancel, registered non-attendance and health care professional involved in the consultation will be measured after 15 mounth
Mortality
Mortality will be measured after 15 months.

Full Information

First Posted
June 27, 2017
Last Updated
November 5, 2020
Sponsor
Annesofie Lunde Jensen
search

1. Study Identification

Unique Protocol Identification Number
NCT03202732
Brief Title
DiabetesFlex - Patient Involvement and Patient-reported Outcome Measures in Type 1 Diabetes
Official Title
DiabetesFlex - Patient Involvement and Patient-reported Outcome Measures in Type 1 Diabetes: A Randomised Controlled Trial and Interview Study
Study Type
Interventional

2. Study Status

Record Verification Date
November 2020
Overall Recruitment Status
Completed
Study Start Date
October 9, 2017 (Actual)
Primary Completion Date
August 20, 2020 (Actual)
Study Completion Date
August 25, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Annesofie Lunde Jensen

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The aim of this study is to investigate the effect of the use of DiabetesFlex in diabetes care compared to standard care in relation to patient involvement and relevance for specific group of persons with T1DM. The investigators hypothesize that the use of DiabetesFlex will lead to a higher degree of patient in-volvement, improved glycaemic control and a decrease in total number of consultations compared to standard care. Furthermore, the investigators aim to identify if a specific sub-population within the T1DM population will benefit significantly from the intervention.
Detailed Description
Diabetes Mellitus (DM) is a chronic condition, and provision of individual and effective diabetes care is a major challenge. The is a lack of evidence on the optimal frequency of attending outpatient clinics for persons with T1DM. The use of patient-reported outcome (PRO) measures in diabetes care area are limited and none existing in a Danish context. This includes studies, which combine PRO measure with diabetes management, patient involvement and self-management. The study will generate knowledge and directions for ways to reframe and to optimize the future management of diabetes care.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type1 Diabetes Mellitus
Keywords
Self-management, Patient Activeted measure, Patient-reported outcome, Type 1 diabetes Mellitus, Non-inferiority study

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
344 (Actual)

8. Arms, Groups, and Interventions

Arm Title
DiabetesFlex
Arm Type
Other
Arm Description
In DiabetesFlex intervention, patients are offered 3 consultations/year. One mandatory consultations (30 minutes). The patient, an endocrinologist and a diabetes nurse attend. Two optional consultations, patients can choose between face-to-face consultations, a telephone consultation or to cancel the consultation. Ahead of the consultations, patients fill out the AmbuFlex Diabetes questionnaire and deliver a blood and urine sample. Based on the patient's response to the AmbuFlex Diabetes questionnaire, the result of the blood sample and the urine sample, the diabetes nurse assign the patient to a face-to-face consultation, a telephone consultation or no consultation with an endocrinologist, a diabetes nurse or a dietician.
Arm Title
Standard care
Arm Type
No Intervention
Arm Description
Standard diabetes care consists of 3 consultations (15 minutes)/year with a physician or a diabetes nurse by turns. Ahead of the consultation patients send in a blood sample for measuring HgA1c, urine sample for measuring urin-albumin creatinin ratio and other blood samples depending of arrangements made in the last consultation. Once a year in relation to a consultation, patients fill in the Problem Area In Diabetes (PAID) (20) scale together. Furthermore, based on the patients or healthcare professional judgement, patients see a dietician when needed.
Intervention Type
Other
Intervention Name(s)
DiabetesFlex
Intervention Description
DiabetesFlex consist of one mandatory and two optional consultations. Before the consultations patients receive the AmbuFlex Diabetes questionnaire. The AmbuFlex Diabetes questionnaire is based on both validated questionnaires and clinical consensus. The AmbuFlex Diabetes questionnaire consists of: SF36 well-being question, WHO-5 Well-being Index. Questions concerning: HgA1c, home-based blood pressure monitoring, incidents of hypoglycemia, diabetes complications, regular eye check, regular food check, erectile dysfunction and peripheral neuropathy, The PAID scale, Topics patients may want to talk with the health care professional about, the patient's evaluation of the need for diabetes care. View the AmbuFlex Diabetes questionnaire at the homepage: www.diabetesflex.auh.dk.
Primary Outcome Measure Information:
Title
HbA1c
Description
Non-inferiority with respect to HbA1c
Time Frame
15 mounth
Secondary Outcome Measure Information:
Title
General health will be assessed by items from the SF-36 questionnaire
Description
General health will be measured at baseline and after 15 mounth
Time Frame
15 mounth
Title
Health literacy will be assessed by The Health Literacy Questionnaire (sub scale 6 and 9)
Description
Health literacy will be measured at baseline and after 15 months.
Time Frame
15 mounth
Title
Well-being will be assessed by the WHO-5 Well-being Index
Description
Well-being will be measured at baseline and after 15 months.
Time Frame
15 mounth
Title
Patient Activated Measure (PAM)
Description
Patient Activated Measure (PAM) will be measured at baseline and after 15 months.
Time Frame
15 mounth
Title
"Generic questions concerning patient involvement" is validate by "DEFACTUM"
Description
Patient involvement will be measured at baseline and after 15 months.
Time Frame
15 mounth
Title
The problem Areas In Diabetes Scale (PAID)
Description
PAID will be measured at baseline and after 15 months.
Time Frame
15 mounth
Title
Blood pressure
Description
Blood pressure will be measured at baseline and after 15 months.
Time Frame
15 mounth
Title
Urine albumine/creatinine ratio
Description
urine albumine/creatinine ratio will be measured at baseline and after 15 months.
Time Frame
15 mounth
Title
Number and type consultations
Description
Consultations consists of face-to-face, telephone, cancel, registered non-attendance and health care professional involved in the consultation will be measured after 15 mounth
Time Frame
15 mounth
Title
Mortality
Description
Mortality will be measured after 15 months.
Time Frame
15 mounth

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age over 18 years Have had T1DM for more than 1 years Be able to use the Danish-language general website on healthcare www.sundhed.dk Be mentally well functioning Understand and read Danish Access to internet
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Annesofie L. Jensen, Postdoc
Organizational Affiliation
Aarhus University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Aahurs University Hospital
City
Aarhus
ZIP/Postal Code
8000
Country
Denmark

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

DiabetesFlex - Patient Involvement and Patient-reported Outcome Measures in Type 1 Diabetes

We'll reach out to this number within 24 hrs